SCHEMBL2409875

SCHEMBL2409875

CC(C)Oc1ncc(B2OC(C)(C)C(C)(C)O2)cc1C(F)(F)F

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 1/20 0.47
S1PR1 P21453 3/20 0.35
CDK1 P06493 1/20 0.34
ALPL P05186 1/20 0.34
PDGFRB P09619 3/20 0.34
KDR P35968 3/20 0.34
DGAT1 O75907 2/20 0.33
FFAR1 O14842 1/20 0.32
LPL P06858 1/20 0.31
LIPG Q9Y5X9 1/20 0.31
GSK3A P49840 1/20 0.31
GSK3B P49841 1/20 0.31
TRPA1 O75762 1/20 0.31
F2 P00734 1/20 0.31
F10 P00742 1/20 0.31
F11 P03951 1/20 0.31
USP30 Q70CQ3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16046359 0.85 AAK1 (0.44) AAK1ALPLPDGFRBKDRDGAT1
SCHEMBL2389323 0.83 AAK1 (0.47) AAK1CDK1ALPLPDGFRBKDR
SCHEMBL16175196 0.82 AAK1 (0.46) AAK1ALPLPDGFRBKDRDGAT1
SCHEMBL1690283 0.80 AAK1 (0.51) AAK1ALPLPDGFRBKDRDGAT1
SCHEMBL365161 0.80 AAK1 (0.44) AAK1S1PR1ALPLPDGFRBKDR
SCHEMBL13975916 0.80 AAK1 (0.46) AAK1ALPLPDGFRBKDRDGAT1
SCHEMBL23275245 0.79 AAK1 (0.40) AAK1PDGFRBKDRDGAT1FFAR1
SCHEMBL17609622 0.77 AAK1 (0.39) AAK1ALPLPDGFRBKDRDGAT1
SCHEMBL16175065 0.76 AAK1 (0.42) AAK1S1PR1ALPLPDGFRBKDR
SCHEMBL30507065 0.76 PDGFRB (0.40) AAK1PDGFRBKDRDGAT1FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2547662-A1 PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS Glaxo Group Limited (GB) 2013-01-23 EP disclosed
US-20130012491-A1 PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2013-01-10 US disclosed
US-20130012491-A1 PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2013-01-10 US disclosed
US-20130012491-A1 PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2013-01-10 US disclosed
WO-2011113309-A1 PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012491-A1 PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS S1PR1, S1PR3, S1PR5 AAK1 612/4885S1PR1 1/4885CDK1 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.